Merck & Co [MRK] vs Gilead Sciences [GILD] Detailed Stock Comparison
Merck & Co
NYSE
Loading...
Gilead Sciences
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Merck & Co wins in 14 metrics, Gilead Sciences wins in 5 metrics, with 1 ties. Merck & Co appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Merck & Co | Gilead Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 12.76 | 22.73 | Merck & Co |
| Price-to-Book Ratio | 4.23 | 7.23 | Merck & Co |
| Debt-to-Equity Ratio | 72.16 | 127.34 | Merck & Co |
| PEG Ratio | -0.72 | 1.05 | Merck & Co |
| EV/EBITDA | 8.25 | 11.66 | Merck & Co |
| Profit Margin (TTM) | 25.79% | 21.87% | Merck & Co |
| Operating Margin (TTM) | 37.47% | 39.16% | Gilead Sciences |
| EBITDA Margin (TTM) | 37.47% | 39.16% | Gilead Sciences |
| Return on Equity | 35.42% | 33.40% | Merck & Co |
| Return on Assets (TTM) | 13.01% | 12.62% | Merck & Co |
| Free Cash Flow (TTM) | $18.10B | $10.31B | Merck & Co |
| Dividend Yield | 3.01% | 3.25% | Gilead Sciences |
| 1-Year Return | -28.53% | 38.33% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 3.25 | 4.92 | Merck & Co |
| Enterprise Value | $233.69B | $160.94B | Merck & Co |
| EV/Revenue Ratio | 3.67 | 5.58 | Merck & Co |
| Gross Profit Margin (TTM) | 77.50% | 78.80% | Gilead Sciences |
| Revenue per Share (TTM) | $25 | $23 | Merck & Co |
| Earnings per Share (Diluted) | $6.49 | $5.04 | Merck & Co |
| Beta (Stock Volatility) | 0.38 | 0.38 | Tie |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Merck & Co vs Gilead Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Merck & Co | -2.75% | -2.24% | 3.13% | 1.21% | -11.29% | -16.50% |
| Gilead Sciences | -2.81% | -0.43% | -4.56% | 2.23% | 0.49% | 24.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Merck & Co | -28.53% | -5.60% | 1.14% | 66.49% | 139.06% | 200.47% |
| Gilead Sciences | 38.33% | 74.62% | 76.10% | 5.63% | 562.91% | 889.21% |
News Based Sentiment: Merck & Co vs Gilead Sciences
Merck & Co
News based Sentiment: MIXED
September was a month of contrasts for Merck, showcasing both promising pipeline developments and challenging operational decisions. While strong earnings and a proactive approach to future growth are positive, the cancellation of the London research hub and declining Gardasil sales introduce uncertainty, resulting in a 'mixed' overall investment story.
Gilead Sciences
News based Sentiment: MIXED
Gilead reported strong Q2 results and is making significant investments in manufacturing and HIV prevention, signaling growth potential. However, continued insider selling and mixed analyst sentiment introduce uncertainty, creating a complex investment picture. The combination of positive financial performance and strategic initiatives alongside these concerns warrants a 'mixed' assessment.
Performance & Financial Health Analysis: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Market Information | ||
| Market Cap | $206.84B | $142.13B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 11,664,882 | 6,749,120 |
| 90 Day Avg. Volume | 11,212,274 | 6,467,877 |
| Last Close | $82.81 | $114.55 |
| 52 Week Range | $73.31 - $119.38 | $81.57 - $121.83 |
| % from 52W High | -30.63% | -5.98% |
| All-Time High | $134.63 (Jun 24, 2024) | $123.37 (Jun 22, 2015) |
| % from All-Time High | -38.49% | -7.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.02% |
| Quarterly Earnings Growth | -0.19% | 0.21% |
| Financial Health | ||
| Profit Margin (TTM) | 0.26% | 0.22% |
| Operating Margin (TTM) | 0.37% | 0.39% |
| Return on Equity (TTM) | 0.35% | 0.33% |
| Debt to Equity (MRQ) | 72.16 | 127.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.57 | $15.84 |
| Cash per Share (MRQ) | $3.45 | $4.88 |
| Operating Cash Flow (TTM) | $18.53B | $9.87B |
| Levered Free Cash Flow (TTM) | $15.56B | $8.84B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.01% | 3.25% |
| Last 12-Month Dividend | $2.39 | $3.91 |
Valuation & Enterprise Metrics Analysis: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 12.76 | 22.73 |
| Forward P/E | 8.81 | 15.42 |
| PEG Ratio | -0.72 | 1.05 |
| Price to Sales (TTM) | 3.25 | 4.92 |
| Price to Book (MRQ) | 4.23 | 7.23 |
| Market Capitalization | ||
| Market Capitalization | $206.84B | $142.13B |
| Enterprise Value | $233.69B | $160.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.67 | 5.58 |
| Enterprise to EBITDA | 8.25 | 11.66 |
| Risk & Other Metrics | ||
| Beta | 0.38 | 0.38 |
| Book Value per Share (MRQ) | $19.57 | $15.84 |
Financial Statements Comparison: Merck & Co vs Gilead Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Revenue/Sales | $15.81B | $6.67B |
| Cost of Goods Sold | $3.56B | $1.54B |
| Gross Profit | $12.25B | $5.13B |
| Research & Development | $4.05B | $1.38B |
| Operating Income (EBIT) | $5.55B | $2.49B |
| EBITDA | $6.96B | $3.28B |
| Pre-Tax Income | $5.00B | $1.65B |
| Income Tax | $571.00M | $334.00M |
| Net Income (Profit) | $4.43B | $1.32B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Cash & Equivalents | $8.63B | $7.93B |
| Total Current Assets | $35.50B | $16.90B |
| Total Current Liabilities | $25.17B | $12.34B |
| Long-Term Debt | $33.48B | $22.15B |
| Total Shareholders Equity | $48.40B | $19.08B |
| Retained Earnings | $66.10B | $10.93B |
| Property, Plant & Equipment | N/A | $7.96B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRK | GILD |
|---|---|---|
| Operating Cash Flow | $6.30B | $1.56B |
| Capital Expenditures | N/A | $-104.00M |
| Free Cash Flow | $1.17B | $1.65B |
| Debt Repayment | $-2.50B | $-1.76B |
| Common Stock Repurchase | $-1.16B | $-730.00M |
Short Interest & Institutional Ownership Analysis
| Metric | MRK | GILD |
|---|---|---|
| Shares Short | 23.83M | 17.56M |
| Short Ratio | 1.96 | 2.79 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 11,664,882 | 6,749,120 |
| Average Daily Volume (90 Day) | 11,212,274 | 6,467,877 |
| Shares Outstanding | 2.53B | 1.25B |
| Float Shares | 2.49B | 1.24B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.81% | 0.91% |
Dividend Analysis & Yield Comparison: Merck & Co vs Gilead Sciences
| Metric | MRK | GILD |
|---|---|---|
| Last 12-Month Dividend | $2.39 | $3.91 |
| Last 12-Month Dividend Yield | 3.01% | 3.25% |
| 3-Year Avg Annual Dividend | $2.77 | $3.30 |
| 3-Year Avg Dividend Yield | 0.71% | 0.91% |
| 3-Year Total Dividends | $8.31 | $9.91 |
| Ex-Dividend Date | Mar 17, 2025 | Sep 15, 2025 |